Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Colorectal Neoplasms 4Neoplasms 3Uterine Cervical Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma Of Esophagus 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 1lenvatinib 1brivanib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Hepatocellular Carcinoma (HCC) × brivanib × Clear all
NCT04212221 2024-07-23

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Zai Lab (Hong Kong), Ltd.

Phase 1/2 Terminated
89 enrolled 23 charts
Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡